Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial

被引：28
|
作者：
Araujo, John C.
Trudel, Geralyn C.
Saad, Fred
Armstrong, Andrew J.
Yu, Evan Y.
Bellmunt, Joaquim
Wilding, George
McCaffrey, John
Serrano, Sergio V.
Matveev, Vsevolod
Efstathiou, Eleni
Oudard, Stephane
Morris, Michael J.
Sizer, Bruce
Goebell, Peter J.
De Bono, Johann Sebastian
Paliwal, Prashni
Durham, Susan
Cheng, Shinta
Logothetis, Christopher
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Seattle Canc Care Alliance, Seattle, WA USA
[3] Univ Hosp Mar, IMIM, Barcelona, Spain
[4] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[5] ICORG, Dublin, Ireland
[6] Hosp Canc Barretos, Sao Paulo, Brazil
[7] NN Blokhin Canc Res Ctr, Moscow, Russia
[8] Univ Athens, Dept Clin Therapeut, Athens, Greece
[9] Georges Pompidou European Hosp, Dept Med Oncol, Paris, France
[10] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, New York, NY 10021 USA
[11] Essex Cty Hosp, Colchester, Essex, England
[12] Univ Erlangen Nurnberg, Dept Urol, D-91054 Erlangen, Germany
[13] Royal Marsden Hosp, Inst Canc Res, Sutton, Surrey, England
[14] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[15] Bristol Myers Squibb Co, Princeton, NJ USA
[16] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Onol, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 06期
关键词：
D O I：
10.1200/jco.2013.31.6_suppl.lba8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA8
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase III SYNERGY trial: Docetaxel ± custirsen and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and poor prognosis.
    Chi, Kim N.
    Higano, Celestia S.
    Blumenstein, Brent A.
    Reeves, James Andrew
    Feyerabend, Susan
    Gravis, Gwenaelle
    Ferrero, Jean-Marc
    Jacobs, Cindy
    De Bono, Johann Sebastian
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] The effect of therapeutic anticoagulation on overall survival (OS) in men receiving docetaxel chemotherapy for metastatic castration-resistant prostate cancer (mCRPC)
    Pratz, Caroline F.
    Brodsky, Robert A.
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [3] Patient Characteristics and Overall Survival (OS) in the Post-Docetaxel Metastatic Castration-Resistant Prostate Cancer (mCRPC) Community Setting
    Cheng, Wendy Y.
    Miao, Raymond
    Duh, Mei Sheng
    Vekeman, Francis
    Sung, Jennifer
    Gauthier-Loiselle, Marjolaine
    Fortier, Jonathan
    Dhawan, Ravinder
    Oh, William K.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 557 - 558
  • [4] A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.
    Morris, Michael J.
    De Wit, Ronald
    Vogelzang, Nicholas J.
    Tagawa, Scott T.
    Higano, Celestia S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.
    Morris, Michael J.
    De Wit, Ronald
    Vogelzang, Nicholas J.
    Tagawa, Scott T.
    Higano, Celestia S.
    Hamberg, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Randomized phase II trial of abiraterone ± dasatinib for patients with metastatic castration-resistant prostate cancer (mCRPC).
    Dorff, Tanya B.
    Quinn, David I.
    Pinski, Jacek K.
    Goldkorn, Amir
    Sadeghi, Sarmad
    Tsao-Wei, Denice
    Groshen, Susan G.
    Kuhn, Peter
    Gross, Mitchell E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [7] Androgens and Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Docetaxel
    Ryan, Charles J.
    Dutta, Sandipan
    Kelly, William K.
    Middleberg, Rob
    Russell, Carly
    Morris, Michael J.
    Taplin, Mary-Ellen
    Halabi, Susan
    CLINICAL GENITOURINARY CANCER, 2020, 18 (03) : 222 - +
  • [8] Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
    Kreis, Kristine
    Horenkamp-Sonntag, Dirk
    Schneider, Udo
    Zeidler, Jan
    Glaeske, Gerd
    Weissbach, Lothar
    BJU INTERNATIONAL, 2022, 129 (04) : 470 - 479
  • [9] Phase II trial of bevacizumab and lenalidomide with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Adesunloye, Bamidele
    Huang, Xuan
    Ning, Yangmin M.
    Madan, Ravi A.
    Gulley, James L.
    Beatson, Melony
    Kluetz, Paul Gustav
    Adelberg, David
    Arlen, Philip M.
    Parnes, Howard L.
    Mulquin, Marcia
    Steinberg, Seth M.
    Wright, John Joseph
    Trepel, Jane B.
    Dawson, Nancy Ann
    Chen, Clara
    Apolo, Andrea Borghese
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [10] Impact of PTEN protein loss on response to docetaxel and overall survival (OS) in metastatic castration resistant prostate cancer (mCRPC) patients
    Rescigno, P.
    Lorente, D.
    Bianchini, D.
    Kolinsky, M.
    Zafeiriou, Z.
    Ferraldeschi, R.
    Mateo, J.
    Recine, F.
    Jayaram, A.
    Rodrigues, D. Nava
    Riisnaes, R.
    Miranda, S.
    Figueiredo, I.
    Crespo, M.
    Mehra, N.
    Perez-Lopez, R.
    Tunariu, N.
    Reid, A.
    Attard, G.
    De Bono, J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S496 - S496
12345